Skip to content

Evaluation Study of SPOTme® Skin Cancer Screenings

Evaluation Study of SPOTme® Skin Cancer Screenings

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03564769
Enrollment
431
Registered
2018-06-21
Start date
2017-12-01
Completion date
2019-06-01
Last updated
2019-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer

Keywords

screening

Brief summary

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Detailed description

Despite tremendous growth in both the interest and volume of skin cancer screenings at the national level, the actual utility and impact of the AAD SPOT me™ skin cancer screening programs have not been fully evaluated. This study will address this knowledge gap. Early detection is vital in the fight against skin cancer, the most common cancer in the United States. While the effects of skin cancer can be devastating, this disease is highly treatable when detected early. This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Interventions

BEHAVIORALIntervention Arm

Individuals randomized to the intervention group will receive skin cancer screening educational materials.

OTHERAAD SPOTmeⓇ skin cancer screening

All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Sponsors

American Academy of Dermatology (AAD)
CollaboratorUNKNOWN
Harvard School of Public Health (HSPH)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participated in the American Academy of Dermatology national screening program in 2016 or 2017 * Have a presumptive diagnosis (screening, non-confirmed) of melanoma * Have provided the AAD with permission to be re-contacted * Have provided the AAD with an email address * Aged 18 years or older * Able to read English

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Completion of a physician skin examinationBaselineSelf-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the period following patient's receipt of an AAD SPOTme® skin cancer screening to the baseline assessment.

Secondary

MeasureTime frameDescription
Completion of a physician skin examination6 monthsSelf-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the 3 months prior to the 6-month follow up assessment
Patient thorough skin self-examination (TSSE)6 monthsSelf-report of patient thorough skin self-examination (TSSE) will be defined as performing at least one TSSE during the 3 months prior to the 6-month follow up assessment
Patient attitude towards sun protection6 monthsSelf-report of patient attitude towards use of sun protection will be defined by likelihood of engaging in sun protection practices in the year following the 6-month follow up assessment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026